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Background
There is still a need of further biomarkers for an early
and correct diagnosis of PAH as mean time between
onset of symptoms and diagnosis is two years. We
investigated markers for pressure overload and markers
for remodeling in two animal models of PAH, in order
to differentiate between biomarker regulation due to
afterload increase based on remodeling of pulmonary
vessels (monocrotaline (MCT)-model) and isolated right
ventricular pressure overload (pulmonary artery (PA)
banding-model). The cGMP enhancing substance Silde-
nafil was utilized to investigate a response-to-treatment
of the markers.
Methods
An equivalent study design was used for the MCT- and
PA banding-study. Male Sprague Dawley rats (250 g
body weight) underwent PA banding surgery or received
60 mg/kg MCT s.c. and were randomized in control,
placebo and treatment group (n=12 per group) in each
study. Treatment with 100 mg/kg Sildenafil in the
drinking water was started on day 14. On day 28 final
hemodynamic measurements were performed and organ
weights were determined. Blood and right ventricular
t i s s u ew e r ew i t h d r a w nf o rd e t e c t i o no fA N P ,B N P ,
MMP-2, TIMP-1 and OPN gene expression levels and
plasma concentrations.
Results
An almost equivalent increase of right ventricular systo-
lic pressure (RVP) and right ventricular hypertrophy was
determined in both models. Gene expression and plasma
concentration of the pressure sensitive markers ANP
(atrial natriuretic peptide) and BNP (brain natriuretic
peptide) were also increased in both models. Gene
expression levels of the remodeling markers TIMP-1
(tissue inhibitor of metalloproteinase-1) and OPN
(osteopontin) and to a less extent of MMP-2 (matrix
metalloproteinase-2) were elevated in both models,
though more pronounced in the MCT-model. Elevated
plasma concentrations of MMP-2, TIMP-1 and OPN
were determined in the MCT-model, but not in the PA
banding-model. A significant response-to-treatment with
Sildenafil, which was only observed for the MCT-model,
was detected for all evaluated markers.
Conclusion
Pathophysiological right ventricular pressure overload
was well represented by ANP and BNP in plasma, which
is a proof of the clinical relevance of those markers.
Whereas plasma MMP-2, TIMP-1 and OPN were not
sufficient to monitor remodeling processes in the right
ventricle due to isolated pressure overload and therefore
failed as cardiac specific markers for right ventricular
remodeling.
Author details
1Pharma Research Centre, Bayer HealthCare, Wuppertal, Germany.
2Martin-
Luther-University, School of Pharmacy, Halle, Germany.
Published: 1 August 2011
doi:10.1186/1471-2210-11-S1-P31
Cite this article as: Grupe et al.: Biomarkers in two different animal
models of pulmonary arterial hypertension (PAH) under treatment with
a cGMP enhancing substance. BMC Pharmacology 2011 11(Suppl 1):P31. * Correspondence: julia.grupe@bayer.com
1Pharma Research Centre, Bayer HealthCare, Wuppertal, Germany
Full list of author information is available at the end of the article
Grupe et al. BMC Pharmacology 2011, 11(Suppl 1):P31
http://www.biomedcentral.com/1471-2210/11/S1/P31
© 2011 Grupe et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.